Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks

J Int Assoc Physicians AIDS Care (Chic). 2009 Mar-Apr;8(2):85-6. doi: 10.1177/1545109709331473.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Drug Administration Schedule
  • Enfuvirtide
  • Female
  • HIV Envelope Protein gp41 / administration & dosage*
  • HIV Envelope Protein gp41 / therapeutic use
  • HIV Fusion Inhibitors / administration & dosage
  • HIV Fusion Inhibitors / therapeutic use
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Integrase Inhibitors / administration & dosage
  • HIV Integrase Inhibitors / therapeutic use
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments / administration & dosage*
  • Peptide Fragments / therapeutic use
  • Pyrrolidinones / administration & dosage*
  • Pyrrolidinones / therapeutic use
  • Quality of Life*
  • Raltegravir Potassium
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • Viral Load*

Substances

  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • HIV Integrase Inhibitors
  • Peptide Fragments
  • Pyrrolidinones
  • Enfuvirtide
  • Raltegravir Potassium